Cureus · 2026
Immediate Glycemic Outcomes Following Simultaneous Pancreas-Kidney Transplantation: Equivalent Early Metabolic Profiles in Type 1 and Type 2 Diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jalalzadeh Mojgan, Mondal Zahidul, Hashmi Nooruddin, Bunin Sonalis, Shah Mital, Shen Jing, Pieloch Daniel P, Khalil Steve, Singh Neeraj, Bongu Advaith, Pelletier Ronald P
Аннотация
BACKGROUND AND OBJECTIVE: Simultaneous pancreas-kidney transplantation (SPKT) is increasingly performed in both type 1 and carefully selected type 2 diabetes mellitus recipients. Although long-term outcomes are well described, early postoperative glycemic behavior remains poorly defined. Persistent hyperglycemia during the early postoperative phase raises concerns regarding potential technical complications or acute rejection after SPKT. In contrast, early normalization of glucose levels suggests pancreas graft viability and sufficient functional beta-cell mass. Despite extensive long-term data, comparative evidence between T1DM and T2DM recipients is limited. This study compares early glycemic trajectories, perioperative glycemic management, and short-term outcomes between these groups.
METHODS: We conducted a single-center retrospective study of adult SPKT recipients from January 2018 to December 2025. Exclusion criteria were multiorgan transplantation beyond SPKT, pancreas graft loss or patient death within 24 hours, and incomplete early postoperative glucose data. Perioperative glucose interventions, pancreatic enzyme markers, and glucose values obtained at predefined postoperative time points (6, 12, and 24 hours; POD 7, 14, and 28) were analyzed. Primary outcomes included early glucose levels and insulin independence at one month, a clinically meaningful indicator of endocrine graft function. Secondary outcomes included delayed graft function, postoperative complications, return to the operating room, pancreatic enzyme levels, and length of hospital stay.
RESULTS: Among 80 SPKT recipients, 31 (38.8%) had T1DM and 49 (61.2%) had T2DM. T2DM recipients were older (50.3 ± 9.3 vs. 41.3 ± 9.3 years, p = 0.001) and had a higher body mass index (27.0 ± 3.5 vs. 24.9 ± 4.0 kg/m², p = 0.016). T1DM recipients, in contrast, had a longer duration of diabetes and lower C-peptide levels (both p < 0.001). Early postoperative glucose values at 6, 12, and 24 hours, as well as on postoperative days 7, 14, and 28, were similar between groups (all p > 0.05). Rates of intravenous insulin use (T1DM: 3/31 [9.7%] vs. T2DM: 7/49 [14.3%]; p = 0.732) and intravenous dextrose administration (23/31 [74.2%] vs. 26/49 [53.1%], p = 0.191) were comparable. No significant differences were observed in pancreatic enzyme levels, insulin dependence at one month, delayed graft function, postoperative complications, or length of hospital stay.
CONCLUSIONS: Early postoperative glycemic control and short-term graft outcomes are comparable between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) SPKT recipients, supporting the safety and applicability of standardized perioperative glycemic protocols across both populations.
METHODS: We conducted a single-center retrospective study of adult SPKT recipients from January 2018 to December 2025. Exclusion criteria were multiorgan transplantation beyond SPKT, pancreas graft loss or patient death within 24 hours, and incomplete early postoperative glucose data. Perioperative glucose interventions, pancreatic enzyme markers, and glucose values obtained at predefined postoperative time points (6, 12, and 24 hours; POD 7, 14, and 28) were analyzed. Primary outcomes included early glucose levels and insulin independence at one month, a clinically meaningful indicator of endocrine graft function. Secondary outcomes included delayed graft function, postoperative complications, return to the operating room, pancreatic enzyme levels, and length of hospital stay.
RESULTS: Among 80 SPKT recipients, 31 (38.8%) had T1DM and 49 (61.2%) had T2DM. T2DM recipients were older (50.3 ± 9.3 vs. 41.3 ± 9.3 years, p = 0.001) and had a higher body mass index (27.0 ± 3.5 vs. 24.9 ± 4.0 kg/m², p = 0.016). T1DM recipients, in contrast, had a longer duration of diabetes and lower C-peptide levels (both p < 0.001). Early postoperative glucose values at 6, 12, and 24 hours, as well as on postoperative days 7, 14, and 28, were similar between groups (all p > 0.05). Rates of intravenous insulin use (T1DM: 3/31 [9.7%] vs. T2DM: 7/49 [14.3%]; p = 0.732) and intravenous dextrose administration (23/31 [74.2%] vs. 26/49 [53.1%], p = 0.191) were comparable. No significant differences were observed in pancreatic enzyme levels, insulin dependence at one month, delayed graft function, postoperative complications, or length of hospital stay.
CONCLUSIONS: Early postoperative glycemic control and short-term graft outcomes are comparable between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) SPKT recipients, supporting the safety and applicability of standardized perioperative glycemic protocols across both populations.